Publications
- Natalizumab in the treatment of multiple sclerosis2011 | First Faculty of Medicine
- Natalizumab in the treatment of patients with multiple sclerosis: first experience2007 | First Faculty of Medicine
- First experiences with Natalizumab in patients with mutiple sclerosisPublication without faculty affiliation
- Peripheral blood mononuclear cell phenotyping in multiple sclerosis patients-different effects of cyclophosphamide and new promising drug natalizumabPublication without faculty affiliation
- Natalizumab in therapy of patients with multiple sclerosis - first experinece +1Publication without faculty affiliation
- Distinct shift in immune cells counts and cerebrospinal fluid oligoclonal bands number after natalizumab treatment in multiple sclerosisPublication without faculty affiliation
- Vliv natalizumabu na lymfocytární subpopulace a oligoklonální pásy v likvoru u roztroušené sklerózyPublication without faculty affiliation
- CD4+ T-cells counts and TH1/Th2 cytokine production after natalizumab treatment in multiple sclerosis patientsPublication without faculty affiliation
- Comparative Effectiveness of Autologous Hematopoietic Stem Cell Transplant vs Fingolimod, Natalizumab, and Ocrelizumab in Highly Active Relapsing-Remitting Multiple Sclerosis2023 | First Faculty of Medicine, Third Faculty of Medicine
- To be or not to be vaccinated: The risk of MS or NMOSD relapse after COVID-19 vaccination and infection2022 | First Faculty of Medicine
Loading network view...